Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard ...

ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple ...

Researchers sought to determine whether CAR-T therapy could improve HR-QoL scores for patients with relapsed or refractory multiple myeloma.

Multiple Myeloma (MM), a chronic and currently incurable hematologic malignancy, remains one of the most dynamic and competitive therapeutic landscapes in oncology. Originating from abnormal plasma ...

The blood cancer multiple myeloma is deadly. This disease is personal for us because one of our best friends and colleagues ...

Johnson & Johnson has new data showing that combining two of its multiple myeloma therapies – Talvey and Tecvayli – has been ...

Like many closely-knit mothers and daughters, Noreen and Anne Hennessy love nothing more than hitting the shops together at ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products ...

Around 1,500 people with multiple myeloma will benefit from belantamab mafodotin, used in combination with bortezomib and ...